Distribution of fluconazole-resistant Candida bloodstream isolates among hospitals and inpatient services in Israel

Clinical Microbiology and Infection

Volumn 19, Issue 8, 2013, Pages 752-756

  Ben Ami, R ^a   Rahav, G ^b   Elinav, H ^c   Kassis, I ^d   Shalit, I ^e   Gottesman, T ^f   Megged, O ^g   Weinberger, M ^h   Ciobotaro, P ⁱ   Shitrit, P ^j   Weber, G ^k   Paz, A ^l   Miron, D ^m   Oren, I ^d   Bishara, J ^e   Block, C ^c   Keller, N ^b   Kontoyiannis, D P ⁿ   Giladi, M ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d RAMBAM MEDICAL CENTER   (Israel)

^e SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^f Wolfson Medical Centre   (Israel)

^g SHAARE ZEDEK MEDICAL CENTER   (Israel)

^h ASSAF HAROFEH MEDICAL CENTER   (Israel)

ⁱ KAPLAN MEDICAL CENTER   (Israel)

^j MEIR MEDICAL CENTER   (Israel)

^k Carmel Medical Centre   (Israel)

^l BNAI ZION MEDICAL CENTER   (Israel)

^m HAEMEK MEDICAL CENTER   (Israel)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Candidaemia; Drug resistance; Epidemiology; Fluconazole

Indexed keywords

FLUCONAZOLE;

ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; CANDIDA; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDEMIA; COMMUNITY HOSPITAL; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; FUNGUS ISOLATION; HEALTH SERVICE; HOSPITAL BED CAPACITY; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPECIES DISTRIBUTION; TERTIARY HEALTH CARE;

CANDIDA; CANDIDA GLABRATA; ISSATCHENKIA ORIENTALIS;

EID: 84880512733     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12004     Document Type: Article

References (19)

1. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-1703.
2. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-1239.
3. Colombo AL, Nucci M, Park BJ et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006; 44: 2816-2823.
4. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-1527.
5. St-Germain G, Laverdiere M, Pelletier R et al. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: report on 453 cases between 2003 and 2005. Can J Infect Dis Med Microbiol 2008; 19: 55-62.
6. Poikonen E, Lyytikainen O, Anttila VJ et al. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis 2010; 10: 312.
7. Poikonen E, Lyytikainen O, Anttila VJ, Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003; 9: 985-990.
8. Chen S, Slavin M, Nguyen Q et al. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006; 12: 1508-1516.
9. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002; 40: 3489-3492.
10. Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-643.
11. Diekema DJ, Messer SA, Brueggemann AB et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002; 40: 1298-1302.
12. Marchetti O, Bille J, Fluckiger U et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004; 38: 311-320.
13. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol 2011; 49: 396-399.
14. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004; 42: 3142-3146.
15. Ben-Ami R, Olshtain-Pops K, Krieger M et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother 2012; 56: 2518-2523.
16. Clinical Laboratory Standards I. Reference Method for Broth Dilution Antifungal Susceptibility testing of Yeasts. Approved Standard M27-A3. Wayne, PA: National Committee for Clinical Laboratory Standards, 2008.
17. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13: 180-195.
18. Pfaller MA, Diekema DJ, Andes D et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14: 164-176.
19. Pfaller MA, Andes D, Arendrup MC et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011; 70: 330-343.